Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dutogliptin in T2DM with Renal Impairment
NCT00958269Phase 3Terminated
- Sponsor
- Phenomix Sciences
- Start
- Aug 2009
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of dutogliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Phenomix Sciences. Primary endpoint: Safety and tolerability of dutogliptin at Day 364. Started Aug 2009; status: terminated.
02
Drugs
dutogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00958269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00958269.